Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Quetiapine for Pediatric Delirium

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~- Any patient in the PICU aged 1 year to 21 years old who is diagnosed with delirium~Exclusion Criteria:~* Age \<1~* Richmond Agitation Sedation Scale (RASS) score of -4 or -5 (deeply sedated or unarousable).~* current treatment for alcohol withdrawal~* hepatic encephalopathy~* pregnancy~* diagnosis of major depressive disorder or bipolar disorder~* diagnosis of movement disorder~* diagnosis of diabetic ketoacidosis~* baseline QTc \>500 milliseconds~* non-English speaking subjects and/or parent/guardian

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 22 Years
- Healthy Volunteers: f

Study Arms:
- Quetiapine (Type: EXPERIMENTAL): A randomized group will receive quetiapine as treatment for delirium.
- Placebo (Type: PLACEBO_COMPARATOR): A randomized group will receive placebo, and not quetiapine.

Based on this trial design, predict the completion outcome and termination type (if applicable).